Studienzentrum Bayenthal Urologische Partnerschaft Köln

The site is conducting a study that compares Ifinatamab deruxtecan with the standard chemotherapy agent docetaxel in patients diagnosed with metastatic castration-resistant prostate cancer. The trial aims to determine whether the new antibody‑drug conjugate can improve overall survival and delay disease progression as measured by radiographic progression-free survival.

• Evaluation of overall survival benefit
• Assessment of radiographic progression-free survival
• Direct comparison with standard chemotherapy
• Focus on advanced disease management

This research, coordinated by the Studienzentrum Bayenthal Urologische Partnerschaft Köln, seeks to offer new therapeutic options for men facing advanced prostate cancer.

A separate trial investigates the safety and efficacy of vepugratinib combined with enfortumab vedotin and pembrolizumab versus placebo in individuals with advanced bladder cancer, specifically targeting urinary bladder neoplasms that have spread. The study evaluates whether the combination can provide clinical benefit while maintaining an acceptable safety profile.

• Safety monitoring of the drug combination
• Efficacy assessment through tumor response
• Exploration of immunotherapy synergy
• Long‑term follow‑up for durability of response

Conducted at Studienzentrum Bayenthal Urologische Partnerschaft Köln, this effort aims to expand treatment possibilities for patients with metastatic bladder cancer.